Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC

Immune checkpoint inhibitor (ICI) therapy has achieved remarkable clinical benefit in melanoma and non-small cell lung cancer (NSCLC). Tumor mutational signatures are the fingerprints of endogenous and exogenous factors that have acted throughout tumorigenesis and heterogeneity; however, their assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Chong, Wei, Wang, Zhe, Shang, Liang, Jia, Shengtao, Liu, Jin, Fang, Zhen, Du, Fengying, Wu, Hao, Liu, Yang, Chen, Yang, Chen, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723771/
https://www.ncbi.nlm.nih.gov/pubmed/33335795
http://dx.doi.org/10.1016/j.omtn.2020.10.033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723771/
https://www.ncbi.nlm.nih.gov/pubmed/33335795
http://dx.doi.org/10.1016/j.omtn.2020.10.033

Ejemplares similares